PRAME derived peptides and immunogenic compositions comprising these
AssigneeAcademisch Ziekenhuis Leiden (H.O.D.N. Lumc)
InventorsJan Kessler, Marieke Griffioen, Cornelis Johannes Maria Melief, Jan Wouter Drijfhout
Life of this patent
Estimating the term…
Abstract
The invention relates to a peptide having a length of no more than 100 amino acids and comprising at least 19 contiguous amino acids from the amino acid sequence of the human PRAME protein, wherein the peptide comprises at least one HLA class II epitope and at least one HLA class I epitope from the amino acid sequence of the human PRAME protein and to its use as such or in a composition as a medicament for the treatment and/or prevention of cancer.
Claims17
An immunogenic pharmaceutical composition comprising (a) a peptide having a length of 27 to 35 amino acids and comprising at least 27 contiguous amino acids from the amino acid sequence of the human PRAME protein and (b) an immune-stimulating amount of a pharmaceutically acceptable adjuvant,
- wherein the peptide comprises at least one HLA class II epitope and at least one HLA class I epitope from the amino acid sequence of the human PRAME protein,
- wherein said HLA class I epitope is capable of activating a CD8+ CTL in a human cancer patient and/or in a healthy control and is represented by the amino acid sequence selected from the group consisting of:
- amino acid sequence including amino acids at positions 100-108 of SEQ ID NO:
- 21;
- amino acid sequence including amino acids at positions 113-122 of SEQ ID NO:
- 21;
- amino acid sequence including amino acids at positions 142-151 of SEQ ID NO:
- 21;
- amino acid sequence including amino acids at positions 190-198 of SEQ ID NO:
- 21;
- amino acid sequence including amino acids at positions 258-267 of SEQ ID NO:
- 21;
- amino acid sequence including amino acids at positions 371-380 of SEQ ID NO:
- 21;
- and
- amino acid sequence including amino acids at positions 425-433 of SEQ ID NO:
- 21;
- wherein said HLA class II epitope is capable of activating a CD45RO positive CD4+ Th cell and is represented by the amino acid sequence selected from the group consisting of:
- amino acid sequence including amino acids at positions 98-124 of SEQ ID NO:
- 21;
- amino acid sequence including amino acids at positions 116-142 of SEQ ID NO:
- 21;
- amino acid sequence including amino acids at positions 133-159 of SEQ ID NO:
- 21;
- amino acid sequence including amino acids at positions 181-207 of SEQ ID NO:
- 21;
- amino acid sequence including amino acids at positions 194-220 of SEQ ID NO:
- 21;
- amino acid sequence including amino acids at positions 234-255 of SEQ ID NO:
- 21;
- amino acid sequence including amino acids at positions 247-273 of SEQ ID NO:
- 21;
- amino acid sequence including amino acids at positions 353-379 of SEQ ID NO:
- 21;
- and
- amino acid sequence including amino acids at positions 424-450 of SEQ ID NO:
- 21, and
- wherein the contiguous amino acid sequence from the human PRAME protein is selected from the group consisting of:
- amino acid sequences SEQ ID NOs:
- 6, 7, 8, 9, 10, 11, 12, 16, and 18.
Dependencies are inferred from the claim text.